Enliven Therapeutics
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 9 in the most recent period (2026/Q3).
- Total institutional ownership rose 5.4 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 118.03% +5.42pp
- Institutions
- 260 +9
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 15 buys · 35 sells
| Name | Role | Stake |
|---|---|---|
| Joseph Lyssikatos | Co-Founder & Research Fellow | 1.01% |
| Samuel Kintz | Co-Founder & Head of Pipeline | 0.89% |
| Anish Patel | Co-Founder & COO | 0.29% |
| Richard Heyman | Former Independent Chairperson | 0.23% |
| Jacob Bauer | Independent Director | 0.12% |
| Lori Kunkel | Independent Director | 0.07% |
| Helen Collins | Chief Medical Officer | 0.03% |
| Rahul Ballal | Director | 0.03% |
| Benjamin Hohl | CFO & Head of Corporate Development | 0.02% |
| OrbiMed Advisors LLC | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-29 | Lori Kunkel | Independent Director | Derivative Exercise and Retained | +11,041 | $1.12–18.30 |
| 2026-10-18 | Helen Collins | Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $2.48–38.47 |
| 2026-10-18 | Benjamin Hohl | CFO & Head of Corporate Development | Derivative Exercise and Sale | -6,018 | $14.85–38.48 |
| 2026-10-13 | Kristine Ball | Director | Other Derivative Acquisition | +23,394 | $39.28 |
| 2026-09-30 | Scott Garland | Director | Derivative Exercise and Sale | -13,000 | $15.47–46.67 |
| 2026-09-16 | Helen Collins | Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $2.48–51.48 |
| 2026-09-16 | Benjamin Hohl | CFO & Head of Corporate Development | Open Market Disposition | -2,036 | $50.72–51.49 |
| 2026-09-16 | Benjamin Hohl | CFO & Head of Corporate Development | Derivative Exercise and Sale | -3,982 | $14.85–50.72 |
| 2026-09-03 | Richard Heyman | Former Independent Chairperson | Intent to Sell (Form 144) | -38,000 | $59.29 |
| 2026-08-16 | Helen Collins | Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $2.48–59.35 |
| 2026-08-16 | Benjamin Hohl | CFO & Head of Corporate Development | Automatic Disposition | -6,018 | $58.35–59.35 |
| 2026-08-03 | Mika Derynck | Independent Director | Derivative Exercise and Sale | -158,795 | $2.48–60.21 |
| 2026-07-16 | Helen Collins | Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $2.48–53.92 |
| 2026-07-16 | Benjamin Hohl | CFO & Head of Corporate Development | Automatic Disposition | -4,946 | $52.32–53.87 |
| 2026-07-16 | Benjamin Hohl | CFO & Head of Corporate Development | Derivative Exercise and Sale | -1,072 | $2.48–52.32 |
| 2026-07-05 | Lori Kunkel | Independent Director | Automatic Disposition | -10,000 | $49.98–50.84 |
| 2026-06-21 | OrbiMed Advisors LLC | -- | Private Disposition | -48,253 | $45.00 |
| 2026-06-21 | OrbiMed Advisors LLC | -- | Open Market Disposition | -811,870 | $45.38 |
| 2026-06-16 | Helen Collins | Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $2.48–44.74 |
| 2026-06-16 | Benjamin Hohl | CFO & Head of Corporate Development | Derivative Exercise and Sale | -6,018 | $2.48–44.75 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Enliven Therapeutics discussion 0 comments